| Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. SA Antoniu Current Opinion in Investigational Drugs (London, England: 2000) 11 (11 …, 2010 | 91 | 2010 |
| Targeting RhoA/ROCK pathway in pulmonary arterial hypertension SA Antoniu Expert opinion on therapeutic targets 16 (4), 355-363, 2012 | 70 | 2012 |
| New therapeutic options in the management of COPD–focus on roflumilast SA Antoniu International journal of chronic obstructive pulmonary disease, 147-155, 2011 | 60 | 2011 |
| Targeting the TNF-α pathway in sarcoidosis SA Antoniu Expert opinion on therapeutic targets 14 (1), 21-29, 2010 | 59 | 2010 |
| Inhaled colistin for lower respiratory tract infections SA Antoniu, I Cojocaru Expert opinion on drug delivery 9 (3), 333-342, 2012 | 58 | 2012 |
| Impact of fatigue in patients with chronic obstructive pulmonary disease: results from an exploratory study SA Antoniu, E Petrescu, R Stanescu, E Anisie, L Boiculese Therapeutic advances in respiratory disease 10 (1), 26-33, 2016 | 54 | 2016 |
| Pirfenidone for the treatment of idiopathic pulmonary fibrosis SA Antoniu Expert opinion on investigational drugs 15 (7), 823-828, 2006 | 49 | 2006 |
| Targeting PDGF pathway in pulmonary arterial hypertension SA Antoniu Expert opinion on therapeutic targets 16 (11), 1055-1063, 2012 | 46 | 2012 |
| Measuring fatigue as a symptom in COPD: from descriptors and questionnaires to the importance of the problem SA Antoniu, D Ungureanu Chronic respiratory disease 12 (3), 179-188, 2015 | 45 | 2015 |
| Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic … SA Antoniu Expert Opinion on Therapeutic Targets 15 (3), 351-353, 2011 | 45 | 2011 |
| Predictors of mortality in patients with COPD and chronic respiratory failure: the quality-of-life evaluation and survival study (QuESS): a three-year study M Carone, S Antoniu, P Baiardi, VS Digilio, PW Jones, G Bertolotti, ... COPD: Journal of Chronic Obstructive Pulmonary Disease 13 (2), 130-138, 2016 | 42 | 2016 |
| MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. SA Antoniu Current opinion in molecular therapeutics 12 (2), 233-239, 2010 | 42 | 2010 |
| Descriptors of dyspnea in obstructive lung diseases SA Antoniu Multidisciplinary respiratory medicine 5, 1-4, 2010 | 40 | 2010 |
| Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. SA Antoniu, MR Kolb IDrugs: the investigational drugs journal 13 (5), 332-345, 2010 | 40 | 2010 |
| Pharmacotherapy of cough-variant asthma SA Antoniu, T Mihaescu, CF Donner Expert opinion on pharmacotherapy 8 (17), 3021-3028, 2007 | 40 | 2007 |
| Determinants of the hesitancy toward COVID-19 vaccination in Eastern European countries and the relationship with health and vaccine literacy: a literature review AD Popa, AI Enache, IV Popa, SA Antoniu, RA Dragomir, A Burlacu Vaccines 10 (5), 672, 2022 | 39 | 2022 |
| Adherence to inhaled therapy in COPD: effects on survival and exacerbations SA Antoniu Expert Review of Pharmacoeconomics & Outcomes Research 10 (2), 115-117, 2010 | 32 | 2010 |
| Anti-TNF-α therapies in chronic obstructive pulmonary diseases SA Antoniu, F Mihaltan, R Ulmeanu Expert opinion on investigational drugs 17 (8), 1203-1211, 2008 | 31 | 2008 |
| Mogamulizumab, a humanized mAb against CC chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. SA Antoniu Current opinion in molecular therapeutics 12 (6), 770-779, 2010 | 30 | 2010 |
| Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa S Antonela Antoniu Expert Review of Anti-infective Therapy 10 (12), 1439-1446, 2012 | 27 | 2012 |
